The 9-0 vote -- covering adults 50 and older across two age groups -- puts Moderna on track to have the first mRNA-based seasonal flu vaccine in the United States, assuming the agency clears it by the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On June 18, Moderna disclosed how a Food and Drug Administration (FDA) advisory committee voted unanimously that the benefits of its mRNA-based flu vaccine, mRNA-1010, outweigh the risks among ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...
Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The Moderna stock rally came after the company shared a major business update on its ...
MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...
Moderna stock was pacing toward its highest close in nearly two years on Friday. But the rally signaled more than an investor rotation away from tech and into defensive biopharma.
Buy Moderna (MRNA). The stock is rerating because it’s moving from “COVID vaccine story” to a real platform: first-in-vivo CAR-T (mRNA-6007) plus multiple oncology/immunology programs. The market is ...
Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028. After running into ...
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...
Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to start a public conversation about how mRNA technology can offer better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results